(D) Routes of delivery: Case studies. (6) Transdermal delivery of peptides and proteins

Christopher Cullander; Richard H. Guy

doi:10.1016/0169-409X(92)90006-C

(D) Routes of delivery: Case studies. (6) Transdermal delivery of peptides and proteins

Christopher Cullander, Richard H. Guy

University of California San Francisco

Research output: Contribution to journal › Review article › peer-review

Abstract

Transdermal drug delivery has attracted considerable attention in recent years and the potential advantages of this mode of administration have been well documented [1]. The transdermal delivery of peptides and small proteins is of particular interest, since percutaneous administration overcomes many of the problems associated with conventional means of administering these potent therapeutic agents. The major obstacles to the passive permeation of peptidic agents are their hydrophilicity and size; however, therapeutically significant dosage levels have been achieved in vivo using either electrical or chemical enhancement.

Original language	English
Pages (from-to)	291-329
Number of pages	39
Journal	Advanced Drug Delivery Reviews
Volume	8
Issue number	2-3
DOIs	https://doi.org/10.1016/0169-409X(92)90006-C
Publication status	Published - 30 Jun 1992

Bibliographical note

Funding Information:
This work was supported by grants (HD-27839) from the National Institutes of Health and Cygnus Therapeutic Systems.

Funding

This work was supported by grants (HD-27839) from the National Institutes of Health and Cygnus Therapeutic Systems.

Keywords

Arginine vasopressin
Enhancer
Insulin
Iontophoresis
Luteinizing-hormone-releasing hormone
Opioid peptide
Polypeptide
Skin
Skin metabolism
Thyrotropin-releasing hormone

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/0169-409X(92)90006-C

Cite this

@article{42713f5f77bc4100a0eaac0d282b1b0d,

title = "(D) Routes of delivery: Case studies. (6) Transdermal delivery of peptides and proteins",

abstract = "Transdermal drug delivery has attracted considerable attention in recent years and the potential advantages of this mode of administration have been well documented [1]. The transdermal delivery of peptides and small proteins is of particular interest, since percutaneous administration overcomes many of the problems associated with conventional means of administering these potent therapeutic agents. The major obstacles to the passive permeation of peptidic agents are their hydrophilicity and size; however, therapeutically significant dosage levels have been achieved in vivo using either electrical or chemical enhancement.",

keywords = "Arginine vasopressin, Enhancer, Insulin, Iontophoresis, Luteinizing-hormone-releasing hormone, Opioid peptide, Polypeptide, Skin, Skin metabolism, Thyrotropin-releasing hormone",

author = "Christopher Cullander and Guy, {Richard H.}",

note = "Funding Information: This work was supported by grants (HD-27839) from the National Institutes of Health and Cygnus Therapeutic Systems.",

year = "1992",

month = jun,

day = "30",

doi = "10.1016/0169-409X(92)90006-C",

language = "English",

volume = "8",

pages = "291--329",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier B.V.",

number = "2-3",

}

TY - JOUR

T1 - (D) Routes of delivery

T2 - Case studies. (6) Transdermal delivery of peptides and proteins

AU - Cullander, Christopher

AU - Guy, Richard H.

N1 - Funding Information: This work was supported by grants (HD-27839) from the National Institutes of Health and Cygnus Therapeutic Systems.

PY - 1992/6/30

Y1 - 1992/6/30

N2 - Transdermal drug delivery has attracted considerable attention in recent years and the potential advantages of this mode of administration have been well documented [1]. The transdermal delivery of peptides and small proteins is of particular interest, since percutaneous administration overcomes many of the problems associated with conventional means of administering these potent therapeutic agents. The major obstacles to the passive permeation of peptidic agents are their hydrophilicity and size; however, therapeutically significant dosage levels have been achieved in vivo using either electrical or chemical enhancement.

AB - Transdermal drug delivery has attracted considerable attention in recent years and the potential advantages of this mode of administration have been well documented [1]. The transdermal delivery of peptides and small proteins is of particular interest, since percutaneous administration overcomes many of the problems associated with conventional means of administering these potent therapeutic agents. The major obstacles to the passive permeation of peptidic agents are their hydrophilicity and size; however, therapeutically significant dosage levels have been achieved in vivo using either electrical or chemical enhancement.

KW - Arginine vasopressin

KW - Enhancer

KW - Insulin

KW - Iontophoresis

KW - Luteinizing-hormone-releasing hormone

KW - Opioid peptide

KW - Polypeptide

KW - Skin

KW - Skin metabolism

KW - Thyrotropin-releasing hormone

UR - http://www.scopus.com/inward/record.url?scp=0026827982&partnerID=8YFLogxK

U2 - 10.1016/0169-409X(92)90006-C

DO - 10.1016/0169-409X(92)90006-C

M3 - Review article

AN - SCOPUS:0026827982

SN - 0169-409X

VL - 8

SP - 291

EP - 329

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

IS - 2-3

ER -

(D) Routes of delivery: Case studies. (6) Transdermal delivery of peptides and proteins

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this